17.55 USD
▲-0.25+8.00%
盘后 16.25 0.00%
2026-08-03
市值
$1.08B
市盈率
—
EPS
-3.72
股息率
—
52 周区间
5.68 – 19.43
成交量
664.28K
Beta
-0.01
目标价
31.64
52W 低 5.6852W 高 19.43
价格走势
公司简介
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysp...